Methods and compositions suitable for improved reattachment of detached cartilage to subchondral bone

Patent metadata

Field	Value
Publication number	US-9827345-B2
Application number	US-201314075146-A
Country	US
Kind code	B2
Filing date	Nov 8, 2013
Priority date	Nov 8, 2012
Publication date	Nov 28, 2017
Grant date	Nov 28, 2017

Abstract

The methods and compositions disclosed herein are effective in the promoting the reattachment of delaminated cartilage to bone. The methods (and related compositions) comprise the removal of the acellular layer of the delaminated cartilage thereby exposing the underlying chondrocyte cells thereby allowing the promotion of the reattachment of the delaminated cartilage.

First claim

The invention claimed is:

1. A method for promoting the reattachment of a delaminated cartilage to a subchondral bone at a cartilage-bone interface comprising:
contacting an acellular layer at a surface on the delaminated cartilage that is proximal to the bone surface with one or more agents contained within a biocompatible adhesive, where the one or more agents are in an amount effective to promote a controlled degradation of the acellular cartilage layer, thereby promoting conditions for the reattachment of said delaminated cartilage to the surface of said subchondral bone, wherein said one or more agents are selected from the group consisting of cytokines, enzymes, and a lattice comprised of polyglycolic acid.

2. The method of claim 1 , wherein said method additionally comprises a subchondral disruption of the bone surface.

3. The method of claim 1 , wherein said method additionally comprises at least partial removal of a calcified cartilage from the bone surface.

4. The method of claim 2 , wherein said subchondral disruption of the bone surface removes from approximately 0.02 mm to approximately 3.0 mm of tissue from the surface.

5. The method of claim 1 , wherein said controlled degradation of said acellular layer comprises promoting an inflammatory reaction.

6. The method of claim 1 , wherein said biocompatible adhesive is a fibrin-based adhesive.

7. The method of claim 1 , wherein the controlled degradation of said acellular layer comprises removing approximately 0.02 mm to approximately 1.0 mm of the cartilage.

8. The method of claim 7 , wherein the controlled degradation of said acellular layer comprises removing approximately 0.1 mm of the cartilage.

9. The method of claim 1 , wherein said cytokines are selected from the group consisting of tumor necrosis factor (TNF), Interleukin-1 (IL-1) and interleukin-6 (IL-6).

10. The method of claim 1 , wherein the acellular layer is also contacted with a crystalline compound comprising a depo-corticosteroid.

Assignees

• Smith & Nephew Inc

Inventors

• Carvell Kelsey Jean
• Cheng Ruth
• Smith Graham
• Burdon Drew

Classifications

• A61L2300/63

  Crystals · CPC title

• A61K9/0024

  Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L) · CPC title

• A61L24/106

  Fibrin; Fibrinogen · CPC title

• A61L2300/426

  Immunomodulating agents, i.e. cytokines, interleukins, interferons · CPC title

• A61L2430/06

  for cartilage reconstruction, e.g. meniscus · CPC title